May 1, 2020
COTA Team

COTA Collaborates to Understand COVID-19 Using Real-World Evidence - New Findings Published

COTA has partnered with Hackensack Meridian Health (HMH), New Jersey’s largest and most comprehensive health network, and Berry Consultants to conduct an observational real world study of more than 3,000 hospitalized COVID-19 patients. The collaboration has created an innovative database known as RE-COV-RY (Real world Evidence-COVid-RegistrY), which is one of the biggest collections of hospital-based COVID-19 data in the United States. 

Using real-world data and evidence, the database produced its first findings on hypertension and ACE/ARB treatments as it relates to COVID-19. The findings have shown that hypertension, the most common coexisting condition, does not have a major impact on survival from the disease when adjusted for age and other comorbid conditions. Similarly, commonly prescribed medications to treat high blood pressure including ACE-inhibitors and ARBs, and Vasotec, Prinivil, Altace, Cozaar, Diovan, and Benicar as well as their generic versions may potentially have a positive impact. 

“We are proud to contribute our expertise in real-world data and analytics capabilities to advance this important research,” said Michael Doyle, COTA President and CEO. “During this unprecedented time, as the healthcare industry unites in the fight against this deadly virus,  COTA is providing valuable clinical insights that will directly impact the treatment of patients affected by COVID-19.”

Roughly three in four hospitalized COVID-19 patients 65 and older had hypertension, the CDC has reported. Evidence  that hypertension is not a major risk factor in COVID-19 mortality when you adjust for age is an important finding as we attempt to identify those who are most vulnerable. The results were released in medRxiv, a leading Yale University-affiliated online platform for researchers to share scientific information prior to publication in peer-reviewed journals. As we continue to learn about COVID-19, the ongoing collaboration between HMH and COTA will continue to produce new clinical findings that will aid in the understanding of this pandemic. 

Read the full findings here.


Next Article:
COVID-19 & COTA: Perspectives from Mike Doyle, CEO
< Back to the COTA blog
Subscribe for the latest posts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

Bringing clarity
to cancer

We are working to ensure that everyone touched by cancer has a clear path to the right care.